Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma ; volume:22 ; number:1 ; day:13 ; month:8 ; year:2022 ; pages:1-15 ; date:12.2022
BMC cancer ; 22, Heft 1 (13.8.2022), 1-15, 12.2022
- Creator
-
Zhang, Genhao
Lv, Xianping
Yang, Qiankun
Liu, Hongchun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09987-2
- URN
-
urn:nbn:de:101:1-2022103121092196102577
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhang, Genhao
- Lv, Xianping
- Yang, Qiankun
- Liu, Hongchun
- SpringerLink (Online service)
Other Objects (12)
MRPL48 is a novel prognostic and predictive biomarker of hepatocellular carcinoma
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Immunotherapy in Hepatocellular Carcinoma
ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Biomarker in Hepatocellular Carcinoma
Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma
Predictive three-biomarker panel in peripheral blood mononuclear cells for detecting hepatocellular carcinoma
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors
Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker
Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response
MRPL48 is a novel prognostic and predictive biomarker of hepatocellular carcinoma
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Immunotherapy in Hepatocellular Carcinoma
ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Biomarker in Hepatocellular Carcinoma
Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma
Predictive three-biomarker panel in peripheral blood mononuclear cells for detecting hepatocellular carcinoma
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors
Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker
Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response
MRPL48 is a novel prognostic and predictive biomarker of hepatocellular carcinoma
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Immunotherapy in Hepatocellular Carcinoma
ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Biomarker in Hepatocellular Carcinoma
Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma
Predictive three-biomarker panel in peripheral blood mononuclear cells for detecting hepatocellular carcinoma
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors
Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker
Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy